Scientific Article| Volume 45, ISSUE 12, P1187.e1-1187.e11, December 2020

Download started.


Outcomes and Early Recurrence Following Enzymatic (Collagenase) Treatment of Moderate and Severe Dupuytren Contractures

Published:August 27, 2020DOI:


      We offer collagenase Clostridium histolyticum (CCH) injections to all patients with a Dupuytren contracture and a palpable cord. We assessed whether more severe contractures respond less well or recur more frequently.


      From a database of 502 CCH injections, 386 (77%) had a complete dataset with minimum 1-year face-to-face follow-up. Contracture severity was assessed using the Tubiana system: grade 1 (27%), grade 2 (49%), grade 3 (19%), and grade 4 (5%). Patients received a single intralesional injection of 0.58 mg CCH followed by manipulation. Finger position was measured at 6 to 12 weeks, 6 months, and 1 year. Failure to break the cord, skin tears, and any adverse events were noted. Recurrence was defined as a failure to maintain any prior correction to within 20°.


      There were 17 failures (4%) and 6 allergic reactions (1%). We found 31% corrected completely, with approximately half remaining corrected at 1 year. We achieved 43° (95% confidence interval, 40°–46°) correction of combined deformity, with 11° (95% confidence interval, 9°–13°) correction attrition over 1 year. Sixteen percent of treated digits experienced a recurrence with no difference between Tubiana grades, and one-third chose further treatment. Following treatment, Tubiana grade 1 contractures improved by 78% in comparison with higher grade contractures (55%–67% relative correction). By 1 year, all grades had a similar mean 46% relative correction. A complete correction was seen in 61% of grade 1 contractures, with more severe contractures less likely to correct completely (9%–24%). A 31% skin tear rate had no impact on outcome, recurrence, or long-term morbidity.


      CCH may treat any Dupuytren cord regardless of severity. Although contracture may recur, few patients pursue further treatment within 1 year.

      Type of study/level of evidence

      Therapeutic IV.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hand Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hurst L.C.
        • Badalamente M.A.
        • Makowski J.
        The pathobiology of Dupuytren’s contracture: effects of prostaglandins on myofibroblasts.
        J Hand Surg Am. 1986; 11: 18-23
        • Rayan G.M.
        Dupuytren disease: anatomy, pathology, presentation, and treatment.
        J Bone Joint Surg Am. 2007; 89: 189-198
        • Hentz V.R.
        Collagenase injections for treatment of Dupuytren disease.
        Hand Clin. 2014; 30: 25-32
        • Crean S.M.
        • Gerber R.A.
        • Le Graverand M.P.
        • Boyd D.M.
        • Cappelleri J.C.
        The efficacy and safety of fasciectomy and fasciotomy for Dupuytren’s contracture in European patients: a structured review of published studies.
        J Hand Surg Eur Vol. 2011; 36: 396-407
        • National Institute for Clinical Excellence
        Needle Fasciotomy for Dupuytren’s Contracture.
        National Institute for Clinical Excellence, London2004
        • Foucher G.
        • Medina J.
        • Navarro R.
        Percutaneous Needle Aponeurotomy: Complications and Results.
        J Hand Surg Br. 2003; 28: 427-431
        • National Institute for Health and Care Excellence
        Collagenase Clostridium histolyticum for Treating Dupuytren’s Contracture.
        National Institute for Health and Care Excellence, London2017
        • Brazzelli M.
        • Cruickshank M.
        • Tassie E.
        • McNamee P.
        • Robertson C.
        • Elders A.
        Collagenase Clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation.
        Health Technol Assess. 2015; 19: 1-202
        • Warwick D.
        • Arner M.
        • Pajardi G.
        • et al.
        Collagenase Clostridium histolyticum in patients with Dupuytren's contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes.
        J Hand Surg Eur Vol. 2015; 40: 124-132
        • Bradley J.
        • Warwick D.
        Patient satisfaction with collagenase.
        J Hand Surg Am. 2016; 46: 689-697
        • Strömberg J.
        • Ibsen-Sörensen A.
        • Fridén J.
        Comparison of treatment outcome after collagenase and needle fasciotomy for Dupuytren contracture: a randomized, single-blinded, clinical trial with a 1-year follow-up.
        J Hand Surg Am. 2016; 41: 873-880
        • Leafblad N.
        • Wagner E.
        • Wanderman N.
        • et al.
        Outcomes and direct costs of needle aponeurotomy, collagenase injection, and fasciectomy in the treatment of Dupuytren contracture.
        J Hand Surg Am. 2019; 44: 919-927
        • Tubiana R.
        Dupuytren's disease of the radial side of the hand.
        Hand Clin. 1999; 15: 149-159
        • Bear B.
        • Peimer C.
        • Kaplan F.T.D.
        • Kaufman G.J.
        • Tursi J.P.
        • Smith T.
        Treatment of recurrent Dupuytren contracture in joints previously effectively treated with collagenase.
        Clostridium histolyticum. J Hand Surg Am. 2017; 42: 391.e1-391.e8
      1. Xiapex collagenase Clostridium histolyticum—Injection Training Brochure. Swedish Orphan Biovitrum AB, Stockholm2015
        • Noland S.
        • Paul A.
        • Pflibsen A.
        • et al.
        Treatment of Dupuytren contracture with collagenase is safe in the anticoagulated patient.
        J Hand Surg Am. 2018; 43: S-44
        • European Medicines Agency
        Annex I—Summary of Product Characteristics. 2016.
        (Available at)
        • Felici N.
        • Marcoccio I.
        • Giunta R.
        • et al.
        Dupuytren contracture recurrence project: reaching consensus on a definition of recurrence.
        Handchir Mikrochir Plast Chir. 2014; 46: 350-354
        • Hurst L.C.
        • Badalamente M.A.
        • Hentz V.R.
        • et al.
        Injectable collagenase Clostridium histolyticum for Dupuytren’s contracture.
        N Engl J Med. 2009; 361: 968-979
        • Rodrigues J.
        • Zhang W.
        • Scammell B.
        • Davis T.R.
        What patients want from the treatment of Dupuytren's disease—is the Unité Rhumatologique des Affections de la Main (URAM) scale relevant?.
        J Hand Surg Eur Vol. 2015; 40: 150-154
        • Macionis V.
        Reliability of the standard goniometry and diagrammatic recording of finger joint angles: a comparative study with healthy subjects and non-professional raters.
        BMC Musculoskelet Disord. 2013; 14: 17
        • Witthaut J.
        • Jones G.
        • Skrepnik N.
        • Kushner H.
        • Houston A.
        • Lindau T.R.
        Efficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies.
        J Hand Surg Am. 2013; 38: 2-11
        • Peimer C.A.
        • Skodny P.
        • Mackowiak J.I.
        Collagenase Clostridium histolyticum for Dupuytren contracture: patterns of use and effectiveness in clinical practice.
        J Hand Surg Am. 2013; 38: 2370-2376
        • Badalamente M.A.
        • Hurst L.C.
        • Benhaim P.
        • Cohen B.M.
        Efficacy and safety of collagenase Clostridium histolyticum in the treatment of proximal interphalangeal joints in Dupuytren contracture: combined analysis of 4 phase 3 clinical trials.
        J Hand Surg Am. 2015; 40: 975-983
        • Bainbridge C.
        • Gerber R.A.
        • Szczypa P.P.
        • et al.
        Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren's contracture.
        J Plast Surg Hand Surg. 2012; 46: 177-183
        • Peimer C.A.
        • Blazar P.
        • Coleman S.
        • Kaplan F.T.
        • Smith T.
        • Lindau T.
        Dupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-year data.
        J Hand Surg Am. 2015; 40: 1597-1605
        • Nordenskjöld J.
        • Lauritzson A.
        • Åkesson A.
        • Atroshi I.
        Collagenase injections for Dupuytren disease: 3-year treatment outcomes and predictors of recurrence in 89 hands.
        Acta Orthop. 2019; 90: 517-522
        • Arora R.
        • Kaiser P.
        • Kastenberger T.J.
        • Erhart S.
        • Gabi M.
        Injectable collagenase Clostridium histolyticum as a nonsurgical treatment for Dupuytren's disease.
        Oper Orthop Traumatol. 2016; 28: 30-37
        • Gaston R.G.
        • Larsen S.E.
        • Pess G.M.
        • et al.
        The efficacy and safety of concurrent collagenase Clostridium histolyticum injections for Dupuytren contractures in the same hand: a prospective, multicenter study.
        J Hand Surg Am. 2015; 40: 1963-1971
        • Warwick D.J.
        • Graham D.
        • Worsley P.
        New insights into the immediate outcome of collagenase injections for Dupuytren's contracture.
        J Hand Surg Eur Vol. 2016; 41: 583-588
        • Zhang D.
        • Earp B.
        • Blazar P.
        Risk factors for skin tearing in collagenase treatment of Dupuytren contractures.
        J Hand Surg Am. 2019; 44: 1021-1025
        • Atroshi I.
        • Nordenskjöld J.
        • Lauritzen A.
        • Ahlgren E.
        • Waldau J.
        • Waldén M.
        Collagenase treatment of Dupuytren’s contracture using a modified injection method: a prospective cohort study of skin tears in 164 hands, including short-term outcome.
        Acta Orthop. 2015; 86: 310-315